Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Evaluating the vulnerability of traditional and transposition FAMM flaps using microdialysis
2022-003858-31Phase 4Completed
- Sponsor
- Aarhus University Hospital
- Start
- Jan 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of cefuroxime and metronidazole in mouth cancer and bacterial disease (2 arms), sponsored by Aarhus University Hospital. Primary endpoints: Ischemic metabolite comparison between conventional and transposition FAMM flaps, Inflammation protein comparison between conventional and transposition FAMM flaps and 5 more. Started Jan 2023; status: completed.
02
Drugs
cefuroximemetronidazole
03
Conditions
mouth cancerbacterial disease
Beyond the preview
Go deeper on 2022-003858-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-003858-31.